08:26 AM EDT, 04/16/2024 (MT Newswires) -- Lexeo Therapeutics ( LXEO ) said Tuesday that its AAVrh.10hFXN-based gene therapy candidate has received fast-track designation from the US Food and Drug Administration to treat Friedreich's ataxia cardiomyopathy.

The candidate, LX2006, is developed to provide a functional frataxin gene for promoting frataxin protein expression and restoring mitochondrial function in myocardial cells, the genetic medicine company added.

Lexeo said it is currently evaluating the safety and tolerability of LX2006 in Sunrise-FA, a phase 1/2 multicenter, 52-week clinical trial.

Shares of the company were up 6% in recent Tuesday premarket activity.